DSIP: Research Overview

The short version

DSIP (delta sleep-inducing peptide) is a small, naturally occurring peptide first isolated in the 1970s from the blood of rabbits during electrically induced sleep, named for its apparent ability to boost slow, deep ("delta") brainwave activity. Despite more than forty years of study, it has no confirmed receptor, gene or precursor — a 2006 review in the Journal of Neurochemistry summarized it as "a still unresolved riddle" whose sleep-promoting evidence is "extremely poorly documented and still weak" ^[14].

It is not approved by the FDA or any major regulator for any use; its international nonproprietary name, Emideltide, has never been attached to an approved drug product. What research exists is a mix of older, small human pilot studies from the 1980s and modern rodent work, including a 2024 study of an engineered DSIP fusion peptide in an insomnia mouse model. People in sleep-optimization and peptide communities also report using it informally, described further down this page as anecdotal, not clinical evidence. This page names no human dose as a recommendation for anyone — only the amounts used in the cited studies themselves.

What it is

DSIP is a linear nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code WAGGDASGE), molecular formula C35H48N10O15. It was first isolated by Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically induced sleep. A naturally occurring phosphorylated form, DSIP-P, is also described in the literature and reported as more potent in some assays than the unphosphorylated form.

Unlike semax and selank, DSIP is not an engineered analog of a larger hormone fragment — it is proposed to be an endogenous signaling molecule in its own right, though its actual physiological role remains genuinely unresolved even after decades of investigation.

How it works

This is the honest, unusual feature of DSIP among the three peptides on this desk: no specific DSIP receptor, gene or precursor protein has ever been conclusively identified. What is documented is a saturable transporter that moves DSIP across the blood-brain barrier and is competitively inhibited by the amino acid L-tryptophan, a dopaminergic relay involved in one of its proposed hormonal effects (sensitive to the dopamine-blocker pimozide), and a proposed but not fully characterized interaction with the endogenous opioid system, inferred partly from early withdrawal-syndrome pilot studies.

A 2006 review concluded that the link between DSIP and sleep itself was never fully characterized: the sleep-promotion hypothesis is "extremely poorly documented and still weak," and — notably — synthetic DSIP analogs, not the native peptide, produced the clearest sleep-promoting effects in the literature the review examined ^[14]. Its dose-response relationship is also reported as parabolic rather than linear, meaning higher doses are not reliably more effective than intermediate ones — a pattern that complicates interpreting any single study in isolation.

What the research shows

Engineered fusion peptide in an insomnia model (2024). A DSIP fusion peptide engineered to cross the blood-brain barrier more effectively (DSIP-CBBBP) reduced average daily wakefulness from roughly 720 to 500 minutes — about a 31% reduction — in mice with drug-induced insomnia, restored melatonin, serotonin and dopamine levels, produced anxiolytic and antidepressant-like behavioral effects, and increased hippocampal neuron density, outperforming unmodified native DSIP in the same model ^[13].

A 2006 review of the evidence base. This review remains the most-cited critical appraisal of DSIP: it concluded no DSIP gene, protein or receptor had been isolated, that the sleep-promoting hypothesis for native DSIP is weakly documented, and that synthetic structural analogs — not the native peptide — showed the clearest sleep effects in the literature reviewed ^[14].

Longevity and tumor incidence in mice (2003). Monthly courses of a DSIP-containing preparation called Deltaran (roughly 100 micrograms per kilogram, five consecutive days per month) in a strain of mice prone to spontaneous tumors increased maximum lifespan by 24.1%, extended the lifespan of the longest-lived 10% of survivors by 17.1%, reduced total spontaneous tumor incidence by a factor of 2.6, and reduced a marker of chromosome damage in bone marrow by 22.6% ^[15]. This is a single-lineage finding from a specific set of related Russian research groups and needs independent replication before being treated as an established effect.

Human HPA-axis study (1989). Intravenous DSIP in men produced a significant reduction in a marker of ACTH activity in blood plasma lasting at least three hours, while cortisol itself was unaffected and followed its normal daily pattern ^[16] — a finding that was not fully reproduced in later human HPA-axis work, per this desk's cited controversies.

Human insomnia pilot (1981). In six middle-aged adults with chronic insomnia, acute intravenous synthetic DSIP improved several measures of disturbed sleep — longer duration, fewer interruptions, slightly more REM sleep — without causing daytime sedation, with the sleep-promoting effect appearing roughly two hours after injection ^[17]. This is one of the field's few controlled human sleep studies and, like the rest of the human evidence, is small and decades old.

Reported effects, cautions & safety

The following are anecdotal, not clinical evidence. They come from sleep-optimization forums and peptide-community discussion, not controlled studies.

Responders describe easier sleep onset, deeper-feeling sleep, vivid dreams and waking without marked grogginess. The necessary counterweight is non-response: many accounts describe no noticeable effect. Others report unpredictable timing, heavy mornings, headache, nausea, dizziness or a fading effect with repeated use. That inconsistency resembles the unsettled formal record but does not prove a mechanism or treatment effect.

The literature supports several cautions:

• DSIP is an unregulated research chemical. No Emideltide product has been approved or marketed, and online material has no pharmaceutical purity or sterility standard.
• Its mechanism remains unknown. No receptor, gene or precursor has been confirmed, and the reported dose-response is non-monotonic rather than predictably stronger with greater exposure ^[14].
• Long-term human safety data are essentially absent. Human work consists mainly of small, older pilots and short neuroendocrine experiments, without a validated human pharmacokinetic profile ^[14][17].
• Persistent sleep problems require a real diagnostic frame. DSIP has not been shown in modern controlled trials to treat a diagnosed sleep disorder.
• Combining it with sedatives, sleep medicines or alcohol is untested, and a poorly defined central-nervous-system action makes interactions difficult to predict.
• Pregnancy and pre-existing medical conditions are unstudied, while reported benefits remain inconsistent ^[14].

Where it fits in Cognitive & Nootropic research

DSIP is the outlier on this desk. Unlike semax and selank, it has no identified receptor, and its core review calls the sleep-promotion hypothesis "extremely poorly documented and still weak" ^[14]. Its place here comes from research on sleep and the HPA stress axis, not a direct neurotrophin mechanism. The recent fusion-peptide work points toward engineered analogs rather than native DSIP as the more active research direction ^[13]. The comparison page sets that uncertainty beside the stronger mechanistic records for semax and selank.